The mAbxience partnership will enable Cipla to continue its ethos of ensuring equitable access to affordable, life-saving medication
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Dupixent peak sales ambition raised to more than €13 billion
Company expects strong organic growth in sales, EBITDA in 2022
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
It is a Phase 3 ready anti-myostatin adnectin for Spinal Muscular Atrophy (SMA).
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Dr. Raman has succeeded Victoria Richon
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
